Suppr超能文献

NeuroX,一个用于研究神经退行性疾病的快速高效基因分型平台。

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases.

作者信息

Nalls Mike A, Bras Jose, Hernandez Dena G, Keller Margaux F, Majounie Elisa, Renton Alan E, Saad Mohamad, Jansen Iris, Guerreiro Rita, Lubbe Steven, Plagnol Vincent, Gibbs J Raphael, Schulte Claudia, Pankratz Nathan, Sutherland Margaret, Bertram Lars, Lill Christina M, DeStefano Anita L, Faroud Tatiana, Eriksson Nicholas, Tung Joyce Y, Edsall Connor, Nichols Noah, Brooks Janet, Arepalli Sampath, Pliner Hannah, Letson Chris, Heutink Peter, Martinez Maria, Gasser Thomas, Traynor Bryan J, Wood Nick, Hardy John, Singleton Andrew B

出版信息

Neurobiol Aging. 2015 Mar;36(3):1605.e7-12. doi: 10.1016/j.neurobiolaging.2014.07.028. Epub 2014 Aug 4.

Abstract

Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.

摘要

我们的目标是设计一个基因分型平台,该平台能够在与常见神经退行性疾病相关的基因突变和风险因素的背景下,对样本进行快速的基因特征分析。该平台需要相对经济实惠、易于部署,并采用常见且易于获取的技术。对于这个项目来说,关键在于我们希望该平台的内容对任何研究者都毫无限制地开放。在设计这个阵列时,我们优先考虑纳入多种类型的基因变异,例如已知的风险等位基因、致病突变、推定的风险等位基因以及其他功能上重要的变体。该阵列主要用于快速筛查样本中的致病突变以及对风险因素进行大规模人群研究。值得注意的是,一个明确的目标是让这个阵列广泛可用,以促进不同疾病之间以及疾病内部的数据共享。由此产生的NeuroX阵列是一种用于高质量基因分型的极具成本效益和时间效率的解决方案。NeuroX包含大约24万个变体的标准Illumina外显子内容主干,以及超过2.4万个专注于神经疾病的定制内容变体。使用12样本格式芯片和常规的Infinium基础设施,每个样本生成数据的成本约为50 - 60美元;因此,基因分型速度快,许多研究者都可以进行。在这里,我们描述了NeuroX的设计,讨论了NeuroX在分析罕见和常见风险变体中的效用,并展示了质量控制指标以及对NeuroX衍生数据进行分析的简要入门指南。

相似文献

1
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases.
Neurobiol Aging. 2015 Mar;36(3):1605.e7-12. doi: 10.1016/j.neurobiolaging.2014.07.028. Epub 2014 Aug 4.
3
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.
4
Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research.
Genetics. 2020 Dec;216(4):905-930. doi: 10.1534/genetics.120.303596. Epub 2020 Oct 16.
5
Interventions targeted at women to encourage the uptake of cervical screening.
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
7
Interventions for preventing falls in older people in care facilities.
Cochrane Database Syst Rev. 2025 Aug 20;8:CD016064. doi: 10.1002/14651858.CD016064.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

引用本文的文献

1
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.
Acta Neuropathol. 2025 May 2;149(1):41. doi: 10.1007/s00401-025-02871-w.
2
Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease.
Cell Rep. 2025 Mar 25;44(3):115355. doi: 10.1016/j.celrep.2025.115355. Epub 2025 Mar 7.
3
Identification of Parkinson's disease using MRI and genetic data from the PPMI cohort: an improved machine learning fusion approach.
Front Aging Neurosci. 2025 Feb 4;17:1510192. doi: 10.3389/fnagi.2025.1510192. eCollection 2025.
4
NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations.
Mov Disord. 2024 Nov;39(11):2039-2048. doi: 10.1002/mds.29902. Epub 2024 Sep 16.
5
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
Mov Disord. 2024 Oct;39(10):1773-1783. doi: 10.1002/mds.29960. Epub 2024 Aug 12.
6
Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia.
Am J Hum Genet. 2024 Jul 11;111(7):1316-1329. doi: 10.1016/j.ajhg.2024.05.017. Epub 2024 Jun 17.
7
8
Association between copy number variations in parkin (PRKN) and schizophrenia and autism spectrum disorder: A case-control study.
Neuropsychopharmacol Rep. 2024 Mar;44(1):42-50. doi: 10.1002/npr2.12370. Epub 2023 Nov 1.
9
Analysis of Y chromosome haplogroups in Parkinson's disease.
Brain Commun. 2022 Oct 28;4(6):fcac277. doi: 10.1093/braincomms/fcac277. eCollection 2022.
10
Universal clinical Parkinson's disease axes identify a major influence of neuroinflammation.
Genome Med. 2022 Nov 16;14(1):129. doi: 10.1186/s13073-022-01132-9.

本文引用的文献

1
Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium.
PLoS One. 2013 Jul 12;8(7):e68095. doi: 10.1371/journal.pone.0068095. Print 2013.
2
An integrated map of genetic variation from 1,092 human genomes.
Nature. 2012 Nov 1;491(7422):56-65. doi: 10.1038/nature11632.
3
Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.
Neurobiol Aging. 2013 Jan;34(1):357.e7-19. doi: 10.1016/j.neurobiolaging.2012.07.017. Epub 2012 Sep 5.
5
Locus-specific mutation databases for neurodegenerative brain diseases.
Hum Mutat. 2012 Sep;33(9):1340-4. doi: 10.1002/humu.22117. Epub 2012 Jul 2.
6
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.
PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.
7
A large study reveals no association between APOE and Parkinson's disease.
Neurobiol Dis. 2012 May;46(2):389-92. doi: 10.1016/j.nbd.2012.02.002. Epub 2012 Feb 12.
8
Chromosome 9 ALS and FTD locus is probably derived from a single founder.
Neurobiol Aging. 2012 Jan;33(1):209.e3-8. doi: 10.1016/j.neurobiolaging.2011.08.005. Epub 2011 Sep 16.
9
A two-stage meta-analysis identifies several new loci for Parkinson's disease.
PLoS Genet. 2011 Jun;7(6):e1002142. doi: 10.1371/journal.pgen.1002142. Epub 2011 Jun 30.
10
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease.
PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验